Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 977 in Gilead Sciences

  1. Drug MNCs eye tie-ups to tap new marketsRead the original story w/Photo

    7 hrs ago | The Telegraph

    ... does not mean that highly regulated markets such as the US or Europe are being left out. Recently, US-based Gilead Sciences Inc joined hands with five Indian companies to manufacture and sell its hepatitis C medicines in 91 developing nations. The ...

    Comment?

  2. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Friday Sep 19 | Business Wire

    ... Zydelig (Idelalisib) per il trattamento della leucemia linfocitica cronica e del linfoma follicolare )--Gilead Sciences, Inc. (Nasdaq:GILD) ha annunciato oggi che la Commissione europea ha concesso l'autorizzazione alla commercializzazione di ...

    Comment?

  3. IBD 50 Stocks Setting Up, Including These 5 MedicalsRead the original story w/Photo

    Friday Sep 19 | Investor's Business Daily

    Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy range or pulled back to their 10-week moving average lines.

    Comment?

  4. EU Approval Of Gilead Sciences, Inc.'s Zydelig Nothing But Good News, Says AnalystRead the original story

    Friday Sep 19 | BioSpace

    September 17, 2014 By Riley McDermid , BioSpace.com Breaking News Sr. Editor News that the European Commission has approved Gilead Sciences, Inc. 's drug Zydelig for two blood cancers means nothing but upside for investors, an analyst with Guggenheim Securities said Friday. The EC approved Zydelig for the treatment of follicular lymphoma and chronic lymphocytic leukemia.

    Comment?

  5. Finding Small Cap Gems Within BiotechRead the original story w/Photo

    Friday Sep 19 | Seeking Alpha

    ... the returns of getting a small cap that becomes a much bigger concern in this space. Just two decades ago Gilead Sciences (NASDAQ: GILD ) was just another small cap equity. It is now a biotech juggernaut whose market capitalization is north of $150 ...

    Comment?

  6. Gilead's Zydelig Approved In EU; Imbruvica In WingsRead the original story w/Photo

    Friday Sep 19 | Investor's Business Daily

    ' drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today . The EC approved the drug for chronic lymphocytic leukemia and follicular lymphoma.

    Comment?

  7. Gilead Sciences Stock Rating Reaffirmed by Citigroup Inc.Read the original story

    Friday Sep 19 | AmericanBankingNews.com

    ... Inc.'s price target would suggest a potential upside of 31.22% from the company's current price. In other Gilead Sciences news, COO John F. Milligan unloaded 146,895 shares of the company's stock on the open market in a transaction that occurred on ...

    Comment?

  8. European Commission Grants Marketing Authorization For Gilead...Read the original story

    Friday Sep 19 | BioSpace

    Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for ZydeligA , 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma . For the treatment of CLL, Zydelig has been approved for use in combination with rituximab for patients who have received at least one prior therapy; or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.

    Comment?

  9. European Commission Grants Marketing Authorization for Gilead's...Read the original story w/Photo

    Friday Sep 19 | Investor's Business Daily

    FOSTER CITY, Calif.-- -- Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for ZydeligA , 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma . For the treatment of CLL, Zydelig has been approved for use in combination with rituximab for patients who have received at least one prior therapy; or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.

    Comment?

  10. Biotech Companies Pushing Sector Higher With Recent Therapeutic...Read the original story

    Friday Sep 19 | Sys-Con Media

    BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. , Eli Lilly and Company , Gilead Sciences Inc. , Celgene Corporation and Arena Pharmaceuticals Inc. GenSpera, Inc. , a leader in developing prodrug therapeutics for the treatment of cancer, announced that the United States District Court for the District of has granted the company's summary judgment with respect to all pending claims asserted against it by Annastasiah Mhaka.

    Comment?

  11. Lawmaker pushes to make new HIV prevention drug more availableRead the original story w/Photo

    Thursday Sep 18 | KTVU Oakland

    Taken daily, Truvada - manufactured by Gilead Sciences of Foster City - is said to provide up to 99 percent protection against HIV transmission. The retail price for a month's supply can range as high as $2,000.

    Comment?

  12. Supervisor Wiener: I'm taking anti-HIV drugRead the original story w/Photo

    Thursday Sep 18 | SFGate

    ... will elevate awareness about PrEP as an available and powerful prevention tool." Truvada, which is made by Gilead Sciences in Foster City, is a single tablet that combines the drugs emtricitabine and tenofovir disoproxil fumarate. If taken daily, it ...

    Comment?

  13. GlobeImmune, Inc. To Present At The 21st Annual NewsMakers In The...Read the original story

    Thursday Sep 18 | BioSpace

    ... targeting brachyury. In October 2011, the Company entered into a worldwide, strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens intended for the treatment of chronic hepatitis B infection. For additional information, please ...

    Comment?

  14. San Francisco Supervisor Scott Wiener Goes Public About HIV Prevention DrugRead the original story w/Photo

    Thursday Sep 18 | CBS Local

    ... he wanted to go public about taking the drug because he felt obliged to get people talking. Truvada, made by Gilead Sciences in Foster City is a pill that if taken daily can cut the risk of HIV infection by up to 99 percent. It's the only drug ...

    Comment?

  15. Gilead Sciences: The Recent Dip In Share Price Creates A Buying OpportunityRead the original story w/Photo

    Thursday Sep 18 | Seeking Alpha

    Gilead Sciences's stock has been on a rocket ship trajectory ever since the launch of its blockbuster drug, Sovaldi. Gilead Sciences Inc. is one of the best performers in the biotech industry.

    Comment?

  16. SF Supe Tells World He Takes Controversial Anti-HIV DrugRead the original story w/Photo

    Thursday Sep 18 | NBC Los Angeles

    ... to choose the methods that are best for them." The Food and Drug Administration approved Foster City based- Gilead Sciences' Truvada (tenofovir plus emtricitabine) for PrEP in July 2012. In May, the Centers for Disease Control and Prevention ...

    Comment?

  17. S.F. supervisor discloses PrEP use in hopes of raising awarenessRead the original story w/Photo

    Wednesday Sep 17 | SFGate

    ... will elevate awareness about PrEP as an available and powerful prevention tool." Truvada, which is made by Gilead Sciences in Foster City, is a single tablet that combines the drugs emtricitabine and tenofovir disoproxil fumarate. If taken daily, it ...

    Comment?

  18. Gilead drug fails in pancreatic cancer studyRead the original story w/Photo

    Wednesday Sep 17 | Business Journal

    One of Gilead Sciences Inc.'s first biologic drugs failed a mid-stage trial in tough-to-treat pancreatic cancer, the company said Wednesday. Simtuzumab, an experimental antibody that Foster City-based Gilead is studying in a range of cancers and fibrotic diseases, did not significantly increase the time pancreatic cancer patients lived without the disease worsening.

    Comment?

  19. Analyst: Gilead Sciences, Inc. Still A Buy After Cancer Drug FailRead the original story

    Wednesday Sep 17 | BioSpace

    September 17, 2014 By Riley McDermid , BioSpace.com Breaking News Sr. Editor News that Gilead Sciences, Inc. 's new pancreatic drug simtuzumab did not significantly increase progression-free survival is not enough reason for investors to exit the stock, an analyst from Guggenheim Partners said late Wednesday. Gilead's double-blind Phase II trial consisted of 236 patients with advanced pancreatic cancer, who received intravenous gemcitabine plus either 200 mg intravenous of simtuzumab, 700 mg of simtuzumab or a placebo in cycles of 28 days.

    Comment?

  20. Gilead Stock Is Falling On These Drug SetbacksRead the original story w/Photo

    Wednesday Sep 17 | Investor's Business Daily

    In addition, the biotech's Phase 2 study results that show its pancreatic cancer treatment failed to show any clinical benefits to patients. Shares of Gilead fell 1.8% to 102.84 in afternoon trading on the stock market today .

    Comment?